初发前列腺癌异质性驱动演化与强激素治疗耐药
研究对37例中高危前列腺癌患者ADT联合恩扎卢胺治疗前活检组织行全外显子测序和免疫组化,发现10q缺失、TP53改变、核ERG表达及导管内癌与不良病理反应相关,肿瘤多样性高者耐药更强。四因素模型预测不良反应AUC 0.89,加基线肿瘤体积后AUC 0.98。
要点
- 10q缺失、TP53改变、核ERG表达和导管内癌提示ADT联合恩扎卢胺反应差。
- 肿瘤组织与基因组多样性高者残留病灶更多、耐药性更强。
- 四因素模型加基线肿瘤体积预测不良反应AUC达0.98。
核心结论
- 部分前列腺癌诊断时即具较高组织学和基因组多样性,这些局限肿瘤更易抵抗强激素治疗。
研究设计与样本
- 37例中高危前列腺癌患者接受6个月ADT联合恩扎卢胺治疗前行靶向活检,组织用于全外显子测序和免疫组化。
主要发现
- 10q缺失(含PTEN)和TP53改变预测不良反应,核ERG免疫组化表达和导管内癌亦为预测因素。
- 不完全反应和无反应肿瘤的肿瘤多样性更高,经系统发育树重建和免疫组化分析评估。
- 四因素二分类模型预测不良反应AUC 0.89,与队列及TCGA 57例Gleason评分8-10前列腺癌验证队列中更高多样性相关。
- 模型加入基线肿瘤体积后区分NADT不良反应AUC 0.98。
关键数值与推荐
- 残留癌负荷以0.05 cm3为切点比较卓越反应者与不完全/无反应者。
临床怎么用
- 对模型识别的不宜ADT反应者,应考虑ADT以外的治疗。
局限性
- 模型前瞻性应用需更多试验活检进行回顾性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients diagnosed with high risk localized prostate cancer have variable outcomes following surgery. Trials of intense neoadjuvant androgen deprivation therapy (NADT) have shown lower rates of recurrence among patients with minimal residual disease after treatment. The molecular features that distinguish exceptional responders from poor responders are not known. OBJECTIVE: To identify genomic and histologic features associated with treatment resistance at baseline. DESIGN, SETTING, AND PARTICIPANTS: Targeted biopsies were obtained from 37 men with intermediate- to high-risk prostate cancer before receiving 6 mo of ADT plus enzalutamide. Biopsy tissues were used for whole-exome sequencing and immunohistochemistry (IHC). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We assessed the relationship of molecular features with final pathologic response using a cutpoint of 0.05 cm3 for residual cancer burden to compare exceptional responders to incomplete and nonresponders. We assessed intratumoral heterogeneity at the tissue and genomic level, and compared the volume of residual disease to the Shannon diversity index for each tumor. We generated multivariate models of resistance based on three molecular features and one histologic feature, with and without multiparametric magnetic resonance imaging estimates of baseline tumor volume. RESULTS AND LIMITATIONS: Loss of chromosome 10q (containing PTEN) and alterations to TP53 were predictive of poor response, as were the expression of nuclear ERG on IHC and the presence of intraductal carcinoma of the prostate. Patients with incompletely and nonresponding tumors harbored greater tumor diversity as estimated via phylogenetic tree reconstruction from DNA sequencing and analysis of IHC staining. Our four-factor binary model (area under the receiver operating characteristic curve [AUC] 0.89) to predict poor response correlated with greater diversity in our cohort and a validation cohort of 57 Gleason score 8-10 prostate cancers from The Cancer Genome Atlas. When baseline tumor volume was added to the model, it distinguished poor response to NADT with an AUC of 0.98. Prospective use of this model requires further retrospective validation with biopsies from additional trials. CONCLUSIONS: A subset of prostate cancers exhibit greater histologic and genomic diversity at the time of diagnosis, and these localized tumors have greater fitness to resist therapy. PATIENT SUMMARY: Some prostate cancer tumors do not respond well to a hormonal treatment called androgen deprivation therapy (ADT). We used tumor volume and four other parameters to develop a model to identify tumors that will not respond well to ADT. Treatments other than ADT should be considered for these patients.
引用
- Wilkinson S, Ye H, Karzai F, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. 2021. PMID: 33785256. doi:10.1016/j.eururo.2021.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。